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Introduction
Malaria is a leading cause of death and disease world⁃
wide, especially in developing countries. Approximately
300 to 500 million people develop malaria and 1.5-3
million, mostly children, die each year［1-3］. Mefloquine
（Lariam ）is one of the most widely used antimalarial
drugs. Because of its long half-life, mefloquine is often
used at moderate, prophylactic doses by travelers and
military personnel. The typical prophylactic dose for
chloroquine resistant faliparum malaria is 250 mg/week
［4］. For severe cases of drug resistant ma－ laria, the
therapeutic dose of mefloquine in the blood is up to 10
times higher than with prophylaxis［5-6］.
With the increased use of mefloquine and higher dos⁃
ing have come increased reports of adverse effects.
Among malarial patients, the risk of adverse effects runs
at approximately 1:1200［7］; however, other studies report
the risk of adverse events to be in the range of 12-90%
［8］. The neurological effects of mefloquine typically oc⁃
cur within 72 h of treatment and are more common in
women than men［7］. Common adverse effects include
anxiety, panic attacks, nightmares, dizziness, tremor,
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Abstract Mefloquine is a widely used anti-malarial drug. Some clinical reports suggest that mefloquine may be oto⁃
toxic and neurotoxic, but there is little scientific evidence from which to draw any firm conclusion. To evaluate the
ototoxic and neurotoxic potential of mefloquine, we treated cochlear organotypic cultures and spiral ganglion cultures
with various concentrations of mefloquine. Mefloquine caused a dose-dependent loss of cochlear hair cells at doses
exceeding 0.01 mM. Hair cell loss progressed from base to apex and from outer to inner hair cells with increasing
dose. Spiral ganglion neurons and auditory nerve fibers were also rapidly destroyed by mefloquine in a dose-depen⁃
dent manner. To investigate the mechanisms underlying mefloquine-induced cell death, cochlear cultures were
stained with TO-Pro-3 to identify morphological changes in the nucleus, and with carboxyfluorescein FAM-labeled
caspase inhibitor 8, 9 or 3 to determine caspase-mediated cell death. TO-Pro-3 -labeled nuclei in hair cells, spiral
ganglion neurons and supporting cells were shrunken or fragmented, morphological features characteristic of cells un⁃
dergoing apoptosis. Both initiator caspase 8（membrane damage）and caspase 9（mitochondrial damage）, along with
executioner caspase 3, were heavily expressed in cochlear hair cells and spiral ganglions after mefloquine treatment.
These three caspases were also expressed in support cells, although labeling was less widespread and less intense.
These results indicate that mefloquine damages both the sensory and neural elements in the postnatal rat cochlea by
initially activating cell death signaling pathways on the cell membrane and in mitochondria.
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headache, fatigue, grand mal, and suicidal ideation［7,
9-16］. When subjective criteria are used, 11-17% of trav⁃
elers report being incapacitated by mefloquine. Milder
CNS disturbances（dizziness, headaches, insomnia）are
seen in up to 25% of individuals with prophylactic doses
and up to 90% with therapeutic doses［7, 17］. Hearing and
balance disturbances have been reported after meflo⁃
quine treatment. One study reported high frequency
hearing loss and tinnitus in 3 patients treated with meflo⁃
quine, with 2 of the 3 patients showing long term hear⁃
ing loss and tinnitus following treatment［18］. In 22 nor⁃
mal healthy volunteers treated with therapeutic doses of
mefloquine（750 mg and 500 mg）［10］, all developed se⁃
vere side effects. The most common complaint was verti⁃
go which was experienced by 96% of subjects, with 73%
developed severe grade 3 vertigo that required bed rest
and medication. Collectively, these results suggest that
prophylactic or therapeutic doses of mefloquine may af⁃
fect the inner ear. However, we are unaware of any sys⁃
tematic investigation of the potential ototoxic effects of
mefloquine on the inner ear. To address this issue, we
treated cochlear organotypic cultures from postnatal day
3（P3）rats with various doses of mefloquine to evaluate
its toxic effects on the sensory hair cells and spiral gan⁃
glion neurons.
Methods
Cochlear organotypic cultures and isolated spiral
ganglion cultures: P3 F344 rats were used for this
study（Charles River Laboratories）. The rat pups were
decapitated and the cochlea removed as described previ⁃
ously［19-20］. The cochlear basilar membrane was microdis⁃
sected out in Hanks Balanced Salt Solution（HBSS, Invit⁃
rogen）and placed on a droplet（15μl) of freshly made
rat-tail collagen gel on the bottom of a 35 mm tissue cul⁃
ture dish. The collagen gel contained rat tail collagen,
10X basal medium eagle（BME）medium and 2% sodi⁃
um carbonate in a ratio of 9:1:1. The cochlear explants
were incubated in 1.2 ml of serum free medium（1X
BME plus serum-free supplement, 1% bovine serum al⁃
bumin, 2 mM glutamine and 20% glucose）in a CO2 in⁃
cubator at 37℃ overnight, and then treated in 2 ml cul⁃
ture medium containing various doses of mefloquine for
24 h.
For isolated spiral ganglion cultures, the cochlear basi⁃
lar membrane containing the organ of Corti and spiral
ganglion was dissected out and then the spiral ganglion
in Rosenthal’s canal was separated from the basilar
membrane. The spiral ganglion neurons were triturated
by a fire-polished Pasteur pipette in a small test tube
containing 500μl DMEM/F-12 with 10% FBS. The sus⁃
pension of dissociated spiral ganglion neurons was seed⁃
ed at a concentration of 100-200 cells/mm2 in a 35 mm
culture dish that had been pre-coated with polylysine
（500 μg/ml) and laminin (20 μg/ml). Spiral ganglion
cultures were stored in an incubator at 37 oC with 5%
CO2 overnight. On the second day, spiral ganglion cul⁃
tures were treated with various doses of mefloquine for
24 h.
Mefloquine treatment: Cochlear organotypic cul⁃
tures were treated for 24 h with 7 different doses of me⁃
floquine（n=10/group): 0 μM (Control), 10 μM, 25 μM,
35 μM, 50 μM, 100 μM and 200μM. The isolated spi⁃
ral ganglion cultures were treated with 50 μM meflo⁃
quine for 24 h.
Sample preparation: At the end of the experiment,
cochlear organotypic cultures and isolated spiral gangli⁃
on cultures were fixed with 4% paraformaldehyde in 0.1
M phosphate buffer（pH 7.4）and stained as described
below. Afterwards, the cochlear basilar membrane or
spiral ganglion cultures were mounted in glycerin on a
glass slides and the cover slipped on.
Staining: After fixation, the specimens were rinsed in
0.1 M phosphate buffered saline（PBS）. For staining
the stereocilia and cuticular plate of the hair cells, the
fixed specimens were incubated in 0.25% Triton X100
for 5 minutes and then immersed in TRITC-labeled
phalloidin（Sigma P1951, 1:200） or FITC-conjugated
phalloidin（Sigma P-5282, 1:200）in PBS for 30 min⁃
utes. Specimens were rinsed three times in 0.1 M PBS
and mounted in glycerin on glass slides.
For staining spiral ganglion neurons and auditory
nerve fibers, the fixed specimens were rinsed in 0.1 M
PBS incubated for 2 h in a blocking solution consisting
of 10% normal goat serum and 10% Triton X-100 in 0.1
M PBS. Afterwards, specimens were immersed in a solu⁃
tion containing 20 μl of mouse anti-neurofilament 200
antibody（Sigma N0142, clone N52）, 20 μl Triton
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X-100（10%）, 6 μl normal goat serum, 154 μl of 0.1 M
PBS for 24 h or 28 h（4 ℃）. Samples were rinsed three
times in 0.1 M PBS and immersed in a solution contain⁃
ing 2 μl of secondary anti-mouse IgG conjugated to
TRITC（Sigma T5393）. Specimens were also labeled
with 1 μl FITC-labeled phalloidin（Sigma P5282, 1:
100）in 12 μl normal goat serum, 40 μl Triton X-100
（10%） and 345 μl of 0.1 M PBS. Specimens were
rinsed three times in 0.1 M PBS and mounted on in glyc⁃
erin on glass slides.
For nuclear staining, fixed specimens were immersed
in a working solution of TO-Pro-3（Invitrogen, T3605）
for 20 minutes. Afterwards, specimens were rinsed and
mounted in glycerin on glass slices.
For staining of activated caspase 8, caspase 9, or cas⁃
pase 3, the culture containing mefloquine were washed
with PBS and fresh medium containing CaspaTag 8（1:
30 in solvent, Intergen）, CaspaTag 9（1:30 in solvent,
Intergen）or CaspaTag 3（1:30 in solvent, Intergen）was
added to the cultures for 1 h［20-21］. These caspase inhibi⁃
tors enter living cells and irreversibly bind to specific ac⁃
tivated caspase present in cells undergoing apoptosis［22］.
Afterwards, specimens were placed in fixative for 3 h,
stained with TRITC-labeled phalloidin for 30 minutes
and mounted in glycerin on glass sides.
Microscopy: Specimens were examined under a fluo⁃
rescence microscope（Zeiss Axioskop）with appropriate
filters for FITC（absorption: 494 nm; emission: 518 nm）,
TRITC or rhodamine（absorption: 544 nm, emission:
572 nm）, or TO-Pro-3（absorption: 642 nm, emission:
661 nm）. Specimens were examined and photographed
with a confocal microscope（BioRad MRC1024）. Imag⁃
es were stored on a PC computer and evaluated with soft⁃
ware（Zeiss LSM Image Examiner, Adobe Photoshop）.
Considering the blue fluorescence of TO-Pro-3 has low
contrast with green fluorescent signal of FITC-labeled
phalloidin, the blue fluorescent signal of TO-Pro-3 la⁃
beling was converted to red fluorescence using the soft⁃
ware LSM Image Examiner.
The research protocol was approved by the University
at Buffalo, Institutional Animal Care and Use Commit⁃
tee in accordance with NIH Guidelines.
Cochleograms: The numbers of missing cochlear out⁃
er hair cells（OHC）and inner hair cells（IHC）were
counted in 0.24-mm segments along the entire length of
the organ of Corti［23］. Using laboratory norms, a cochleo⁃
gram was constructed showing the percentage of missing
hair cells（IHC plus OHC）as a function of percent dis⁃
tance from the cochlear apex. To aid in the analysis, av⁃
erage cochleograms were reconstructed for each group of
animals.
Results
Mefloquine hair cell damage: Figure 1A-F shows typi⁃
cal photomicrographs from the middle segment of the co⁃
chlea labeled with FITC-conjugated phalloidin. Intense
labeling is seen on IHC and OHC stereocilia bundles
and to a lesser extent the cuticular plate allowing easy
identification of hair cells and their stereocilia. Untreat⁃
ed control cochlea showed little or no evidence of hair
cell loss and normal OHC and IHC morphology after 24
h in culture（Figure 1A）. Treatment with 25 μM meflo⁃
quine caused considerable stereocilia disarray, but mini⁃
mal hair cell loss（Figure 1B）. Increasing the dose to 35
μM resulted in increased stereocilia damage and consid⁃
erable loss of both OHC and IHC. Cochlear hair cell
damage was more severe in the basal high frequency re⁃
gion than in the middle or apical region of the cochlear
cultures. Increasing the dose of mefloquine to 100 μM
destroyed nearly 100% OHC and IHC in the middle
turn, as well as most supporting cells（Figure 1D）.
To quantify the degree and location of the hair cell
loss, cochleograms showing percent hair cell loss (OHC
plus IHC）as function of percent distance from the apex
were prepared from six cochlear cultures in each meflo⁃
quine treatment group. Mean cochleograms for 10, 25,
35, 50, 100 and 200 μM mefloquine are shown in Fig⁃
ure 2. Little or no hair cell loss was seen with 10 μM me⁃
floquine（Figure 2A）. However, 25 μM mefloquine re⁃
sulted in nearly 100% loss in the extreme base which de⁃
clined to less than 10% loss near the middle of the co⁃
chlea. In the extreme apex, hair cell loss was approxi⁃
mately 20%. Mefloquine at 35 μM caused massive loss
of hair cells in the basal 50% of the cochlea（Figure
2C）. When the dose was increased to 50 μM, more than
80% of the hair cells were destroyed along the entire
length of the cochlea（Figure 2D）. Treatment with 100
μM or 200 μM resulted in nearly 100% hair cell loss
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throughout the entire cochlea（Figure 2E, 2F）.
To determine if mefloquine also damaged the afferent
nerve fibers, cochlear organotypic cultures were immu⁃
nolabeled with a neurofilament 200 kD antibody and
TRITC-conjugated secondary antibody for spiral gangli⁃
on neurons. Specimens were also labeled with
FITC-phalloidin for hair cells. Figure 3 shows typical
confocal photomicrographs from a normal culture and
cultures treated with mefloquine for 24 h. In normal co⁃
chlear cultures, large fascicles of nerve fibers project
out to the IHC and fewer to the OHC（Figure 3A）. In
cultures treated for 24 h with 35μM of mefloquine, most
of the nerve fibers and hair cells in the base of the co⁃
chlea were missing（Figure 3B）. In cultures treated with
Fig.1 Typical morphologic features of control and mefloquine-treated cochlea after 24 h in culture. Specimens are stained
with FITC-phalloidin.（A）Control with three orderly rows of OHC and one row of IHC. OHC stereocilia are arranged in a
broad U-shape; IHC stereocilia are arranged in a gently curving arc.（B）Stereocilia disarray in most hair cells after treat⁃
ment with 25 μM mefloquine.（C）Increased stereocilia damage, loss of OHC（arrowheads）and missing IHC (arrows) after
treatment with 35 μM mefloquine.（D）Nearly complete hair cell loss after treatment with 100 μM mefloquine.
Fig.2 Average（n=6/group）cochleograms showing percent missing hair cells as function of percent distance from the apex 24 h af⁃
ter treatment with different doses of mefloquine.（A）Little or no hair cell loss with 10 μM of mefloquine.（B-F）Progressive in⁃
creases in hair cell loss as the dose of mefloquine increased（25, 35, 50, and 100μM）.
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50 μM mefloquine for 24 h, most of the nerves in both
the base and apex of the cochlea were missing（Figure 3
C, D）, and most of the hair cells were missing in the
base and apex except for some residual hair cells in the
apex with severe stereocilia pathology. Cochlear cultures
were labeled with an antibody against neurofilament 200
kD. In normal cochlear cultures, numerous nerve fiber
bundles project radially towards the hair cells（Figure
4A）. Treatment with 50, 100 or 200 μM mefloquine de⁃
stroyed the nerve fibers; fibers disintegrated into small
fragments or puncta（Figure 4B-D）.
To determine the mechanisms underlying meflo⁃
quine-induced hair cell death, cochlear cultures were
treated with 35 μM mefloquine for 24 h, a dose that de⁃
stroys approximately 50% of the hair cells. Afterwards,
specimens were stained with TO-Pro-3 to search for evi⁃
dence of DNA fragmentation, a hallmark of apoptosis.
In normal cochlear cultures, large, round TO-Pro-3 nu⁃
clei（pseudo red）are evident in phalloidin-labeled hair
cells. They are also present in supporting cells（Figure
5A）. After treatment for 24 h with 50 μM mefloquine,
many hair cells in the middle turn of the cochlea were
missing or severely damaged. TO-Pro-3 nuclei in dam⁃
aged hair cells were condensed or fragmented（Figure
Fig.3 Photomicrographs showing hair cells labeled with FITC-phalloidin (green) and nerve fibers labeled with neurofilament 200
kD（red）.（A）Photomicrograph from the apical turn of a culture treated with 35 mM mefloquine, a dose that causes minimal dam⁃
age in the apex of the cochlea. Note three rows of OHC and one row of inner hair cells and nerve fiber bundles projecting out to⁃
wards the hair cells.（B）Photomicrograph from the same cochlear tissue as in panel A, but from the basal turn of the cochlea. Note
severe damage to both cochlear hair cells and auditory nerve fibers 24 h after 35 μM mefloquine treatment.（C）Cochlear tissue
from the apical turn showing almost complete destruction of both hair cells and nerve fibers 24 h after 50 μM mefloquine treatment.
（D）Same cochlear culture as in panel C, but photomicrograph taken from the basal turn. Note the nearly complete loss of hair
cells and spiral ganglion neurons.
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5B）, morphological features of apoptosis.
To further characterize the mechanisms underlying
mefloquine-induced cell death, cochlear cultures were
labeled with fluorogenic probes against extrinsic, initia⁃
tor caspase 8, intrinsic, initiator caspase 9, or execution⁃
er caspase 3. Strong caspase 8（Figure 6A）and caspase
9（Figure 6B）labeling occurred in hair cell and support⁃
ing cells regions after 24 h treatment with 35 μM meflo⁃
Fig.4 Photomicrographs of cochlear cultures stained with an antibody against neurofilament 200 kD.（A）Thick bands of
nerve fibers projecting radially towards the hair cells.（B-D）Photomicrographs from cochlear cultures treated for 24 h with
50（B）, 100（C）or 200（D）μM mefloquine. Note disintegration of nerve fibers into small beads or puncta.
Fig.5 Cochlear surface preparations from the middle turn of the cochlea labeled with FITC-conjugated phalloidin
（green）and TO-Pro-3（red）.（A）Normal cochlea showing green phalloidin-labeled OHC and IHC with large,
round TO-Pro-3 labeled nuclei. Note TO-Pro-3 labeling of support cell（SC）nuclei.（B）24 h after 50 μM meflo⁃
quine treatment, nuclei of hair cells were condensed, fragmented（arrows）or completely missing. Note absence of
TO-Pro-3 nuclei in supporting cells.
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quine. Downstream executioner caspase 3 was evident
in a few supporting cells and hair cells（Figure 6C）, but
labeling was less widespread than for caspase 8 or cas⁃
pase 9. In isolated spiral ganglion cultures treated for 24
h with 50 μM mefloquine, caspase 8, caspase 9, and cas⁃
pase 3 labeling were present in many neurons. Labeling
intensity of caspase 8 and caspase 3 tended to be greater
than that of caspase 9（Figure 7, B-D）. In contrast, cas⁃
pase 3 labeling was absent from control cultures. Meflo⁃
quine also induced shrinkage of spiral ganglion soma, a
Figure.6 Cochlear cultures from the middle turn labeled with TRITC-labeled phalloidin（red）and fluorogenic probes against activated
caspase 8, caspase 9 or caspase 3 (green). Samples have been treated for 24 h with 35 μM mefloquine.（A）Caspase 8 expressed in both
hair cells（HC）and supporting cells (SC). (B) Caspase 9 expressed in hair cells (HC) and supporting cells（SC）.（C）Labeling with cas⁃
pase-3（green or yellow）, an executioner caspase downstream of caspase-8 and caspase-9, is present, but less intense than caspase 8
or caspase 9.
Figure.7 Isolated spiral ganglion neuron cultures labeled with neurofilament 200 kD antibody（red）and fluorogenic probes
against activated caspase 8, caspase 9, or caspase 3（green）.（A）Normal spiral ganglion cultures showing no Caspase 3.（B）
Caspase-8 activated in spiral ganglion neurons 24 h after 50 μM treatment with mefloquine.（C）Caspase 9 activated in spiral
ganglion neurons 24 h after 50 μM mefloquine treatment.（D）Caspase 3 activated in spiral ganglion neurons 24 h after 50 μM
treatment with mefloquine
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classic feature of cells undergoing apoptosis.
Discussion
Although some reports indicate the mefloquine may
be neurotoxic［24-25］, the results of the current study are
the first to demonstrate severe ototoxic damage to hair
cells, supporting cells and spiral ganglion neurons in rat
cochlear cultures treated with mefloquine. Meflo⁃
quine-induced damage increased rapidly with dose.
The 10 μM dose of mefloquine failed to induce hair cell
or nerve fiber damage whereas the 25 μM dose damaged
hair cells in the base of the cochlea（Figure 1-2）. Dou⁃
bling the dose from 25 to 50 μM caused widespread
damage throughout the cochlea and 100 mM destroyed
nearly 100% of the hair cells and neurons（Figure 2-4）.
Severe hair cell loss was first observed in the base of
the cochlea 24 h after treatment with 25 μM meflo⁃
quine; with higher doses the damage spread towards the
apex. Thus, the ototoxic effects of mefloquine show a
damage gradient that spreads from base to apex with in⁃
creasing dose similar to other ototoxic drugs ［21, 26-28］.
Since concentration of mefloquine in culture is similar
throughout the medium, the stereotypic pattern of hair
cell loss may reflect differences in mefloquine uptake in⁃
to cells in the base versus the apex. Alternatively, the
tonotopic gradient of cell loss may be related to the in⁃
trinsic differences in the antioxidant properties of hair
cells in the base versus the apex［29］.
While many antimalarial drugs can induce pro-apop⁃
totic effects, the apoptotic effects of mefloquine are not
well understood except in enucleated cells ［30-34］. In our
cochlear cultures, mefloquine-mediated hair cell loss
and spiral ganglion degeneration appeared to occur pre⁃
dominantly by apoptosis. Mefloquine induced nuclear
fragmentation and condensation and shrinkage of the
spiral ganglion soma（Figure 5, 7）, morphological fea⁃
tures of apoptosis［35-37］. Programmed cell death was initi⁃
ated through both the extrinsic, membrane-based cell
death pathway as reflected in caspase 8 upregulation
and the intrinsic, mitochondrial-based cell death path⁃
way as indicated by caspase 9 activation（Figure 6-7）.
Activation of downstream, executioner caspase 3 also oc⁃
curred, but tended to be less widespread than caspase 8
or caspase 9. Caspase-8 is activated in response to re⁃
ceptors on the cell’s membrane with a death domain
that interacts with FADD or TRADD ［38-41］. In contrast,
Caspase-9 is activated in response to mitochondrial
stress that leads to the release of cytochrome c from mi⁃
tochondria, which then interacts with Apaf-1, causing
self-cleavage and activation of caspase-9［42-44］. The exe⁃
cutioner caspase-3 is downstream of the initiator cas⁃
pase-8 and caspase-9 and acts to cleave various targets
leading to cell death［45］.
The specific mechanisms that initiate mefloquine-in⁃
duced cell death in cochlear cultures remain unclear.
Mefloquine disrupts the endoplasmic reticulum in neu⁃
rons causing an increase in intracellular calcium［46］. Me⁃
floquine also increases the influx of extracellular calci⁃
um into neurons by an unknown pump［46］. High calcium
concentrations may damage mitochondria leading to acti⁃
vation of caspase-9 ［45, 47-48］. The influx of calcium could
also activate calpains, a family of calcium-dependent
neutral cysteine proteases that promote the breakdown
of proteins, kinases, phosphatases and transcription fac⁃
tors［49］, leading to cell death by apoptosis or necrosis. Fi⁃
nally, mefloquine blocks gap junction proteins Cx36 and
Cx50 at nM and Cx43, Cx32, and Cx26 at micromolar
concentrations. Cx43 and C26 are expressed at high lev⁃
els in the inner ear and could represent another pathway
by which mefloquine could damage the inner ear［50］.
Our results indicate that mefloquine is highly toxic to
developing postnatal cochlear organotypic cultures.
These findings are consistent with previous reports indi⁃
cating that mefloquine is teratogenic in animals ［51］.
Whether or not mefloquine exerts the same level of toxic⁃
ity in adult hair cells or spiral ganglion neurons is un⁃
clear. Future in vitro or in vivo experiments are needed
to answer this question.
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